FindTrial
Sign In

EFFECTS OF TREATMENT WITH L-ARGININE ASSOCIATED TO N-ACETILCYSTEINE IN PATIENTS WITH CORONARY ISCHEMIC CARDIOPATHY EVALUATED WITH MYOCARDIAL SPECT (TC99) WITH EXERCISE

EFFECTS OF TREATMENT WITH L-ARGININE ASSOCIATED TO N-ACETILCYSTEINE IN PATIENTS WITH CORONARY ISCHEMIC CARDIOPATHY EVALUATED WITH MYOCARDIAL SPECT (TC99) WITH EXERCISE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002072-15-IT
Enrollment
Unknown
Registered
2005-07-01
Start date
2005-07-01
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TO IMPROVE CORONARY PERFUSION INCREASING THE PRODUCTION OF NITRIC OXIDE IN CORONAROPATHIC DIABETIC SUBJECTS BY MEANS OF ARGININE AND ACETYLCYSTEINE ADMINISTRATION MedDRA version: 6.1 Level: PT Classification code 10061815

Interventions

Trade Name: N-ACETILCISTEINA EG *20CPREF Product Name: NA Product Code: NA Pharmaceutical Form: Effervescent tablet INN or Proposed INN: Acetylcysteine CAS Number: 616-91-1 Concentration unit: mg mill

Sponsors

AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026